Unlike the traditional view that TIMP-2 is considered an MMP inhibitor, ours is the first study to investigate the TIMP-2 genome and identify that the rs12600817 polymorphism can affect the development of severe ROP in premature infants. Here, TIMP2 is linked to retinopathy of prematurity.